Skip to content
2000
Volume 15, Issue 16
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Over the last years a number of reports have described elevated numbers of regulatory T (Treg) cells inside of tumors, in close proximity of the tumor, draining lymph nodes and also in peripheral blood of patients with solid tumors and hematologic malignancies. There is increasing evidence that Treg cells can migrate into tumors and suppress effective anti-tumor responses in the tumor microenvironment, thus contributing to the prosperity and growth of human tumors. In addition, several mechanisms have been described how conversion of conventional CD4+ T cells into Treg cells can occur in the context of human tumors, yet little is known about the molecular and cellular features responsible for the increase and maintenance of elevated levels of Treg cells in cancer. Recent studies now have elucidated how Treg cells mediate regulatory activity in the tumor microenvironment and enhanced our understanding of the underlying molecular mechanisms. Targeting Treg cells therefore provides an attractive therapeutic strategy to potentially influence the suppressed immune response in tumor patients thereby altering and supporting anti-tumor therapy.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/138161209788453211
2009-06-01
2025-04-19
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/138161209788453211
Loading

  • Article Type:
    Research Article
Keyword(s): FOXP3; Regulatory T cells; tumor immunology
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test